WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has entered into a strategic cooperation framework agreement with Hong Kong Science and Technology Parks Corp. The partnership aims to promote the establishment of a Contract Research, Development, and Manufacturing Organization (CRDMO) value chain in Hong Kong, focusing on the development of antibody drug conjugates (ADCs) and broader bio-conjugated drugs.
Promoting Biotech Development in Hong Kong
Through this collaboration, WuXi XDC and Hong Kong Science and Technology Parks Corp will leverage comprehensive services and capabilities to advance the development of ADCs and other bio-conjugated drugs. The partnership will also strengthen the biotechnology ecosystem in Hong Kong by fostering collaboration between industry, academia, and research institutions, with a focus on talent training and development.
Comprehensive Services and Industry Engagement
Enterprises within the Technology Park ecosystem will have access to WuXi XDC’s one-stop service platform, which includes drug discovery, development, and analytical services. This platform is designed to accelerate the development of ADCs and other bio-conjugated drugs. WuXi XDC will also enhance communication with Hong Kong biotechnology enterprises and research institutions through consultation and training, facilitating the translation of scientific research into practical applications.
Future Collaboration and Ecosystem Development
Both parties will deepen the integration of ecosystem resources, regularly hold exchange activities, and develop a cooperation roadmap. These efforts are aimed at promoting the establishment of a CRDMO value chain in Hong Kong and accelerating the development and marketing of innovative drugs, thereby contributing to the growth of the region’s biotechnology sector.-Fineline Info & Tech
